

FOR IMMEDIATE RELEASE

STELLAR BIOTICS ENTERS METABIOTIC SUPPLEMENT, DEL-IMMUNE V[®], INTO PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF STAGE III COLORECTAL CANCER

The Study, in Collaboration with Hermanos Ameijeiras Surgical Clinical Hospital in Havana, Cuba, will Help Reduce Post-Surgical Side Effects and Improve Quality of Life for Cancer Patients

ROCKLEIGH, NJ – December 1, 2022 - [Stellar Biotics](#) today announced the initiation of a Phase 1 clinical trial to evaluate [del-IMMUNE V[®]](#), the leading metabiotic supplement on the U.S. market, as a nutritional supplement for stage III colorectal cancer patients undergoing post-surgical adjuvant therapy to reduce the inflammatory process and improve the quality of these patients' lives.

The study, designed and conducted as a randomized and double blind, placebo-controlled trial, is a collaborative effort between Stellar Biotics and the renowned medical and research team of the Hermanos Ameijeiras Surgical Clinical Hospital, in Havana, Cuba. The study involves patients with stage III colorectal cancer, and it is intended to demonstrate that the use of del-IMMUNE V (100 mg) during this phase will help reduce the adverse effects of post-surgical treatments and promote a better experience for patients in recovery.

“Post-surgery colorectal cancer therapy is traditionally a six-month process rife with adverse symptoms including gastrointestinal distress such as diarrhea, difficulties with urination and defecation, stomach dysbiosis and other debilitating side effects of chemotherapy and radiotherapy. We expect that the unique composition of del-IMMUNE V as an immunomodulator and anti-inflammatory, will reduce these effects and offer an improved lifestyle for these recovering patients,” said Dr. Liubov Sichel, co-founder, chief scientific officer and chief executive officer of Stellar Biotics.

“This partnership is an exciting one as it furthers our joint commitment to conducting biomedical research and clinical trials in coordination with other scientific institutions for the improvement of human health,” said Gissel García PhD, Head Researcher and Associate Professor, Pathology Department, Hermanos Ameijeiras Surgical Clinical Hospital. “We are hopeful that this trial will substantiate the positive impact del-IMMUNE V can make on the lives of these recovering patients.”

del-IMMUNE V is an all-natural metabiotic supplement developed by Stellar Biotics; it is proven safe and effective and noted as the leading non-prescription cell-fragment supplement backed by clinical research on the U.S market. It contains bacterial cell surface molecules – fragments of cell wall components, DNA motifs and essential peptides and amino acids – that activate the innate immune system. These compounds also stimulate and regulate inflammatory processes at the cellular level. Its usefulness as a stimulant of the immune system has been

demonstrated, both in acute conditions such as bacterial, viral, and fungal infections of different types and chronic conditions such as asthma, fibromyalgia, hepatitis C, among others.

In previous [clinical trials](#) del-IMMUNE V showed significant positive effects on immune system function during food allergy treatments and activation of the body's antiviral protection mechanisms, leading to the potential prevention of acute respiratory viral infections. del-IMMUNE V is proven, and has been for decades, to be a complementary immune support supplement to patients undergoing chemotherapy or radiotherapy because it stimulates the proliferation of stem cells, white blood cells and stimulates growth of microbiota necessary to suppress pathogenic bacteria and viruses.

To learn more about Stellar Biotics, visit stellarbiotics.com

About Stellar Biotics LLC

Established in 2002, by esteemed microbiologist, Dr. Liubov Sichel, Stellar Biotics (formerly Pure Research Products, LLC), manufactures all-natural immune and gut health supplements formulated with del-IMMUNE V[®], the leading metabiotic supplement and next generation of probiotics. del-IMMUNE V is derived from a unique strain of *Lactobacillus rhamnosus* (*Lactobacillus rhamnosus* DV - NRRLB-68023) through Stellar Biotics proprietary Cell Fragment Technology™ to provide immediate broad-spectrum immune system support and balance and heal the gut microbiome. It is the leading non-prescription cell-fragment supplement backed by clinical research on the U.S market.*

Stellar Biotics, in addition to del-IMMUNE V, offers a full line of human and pet immune and gut health products that are manufactured in the U.S. and available worldwide. For more details visit stellarbiotics.com or follow us on social @stellarbiotics

About Hermanos Ameijeiras Surgical Clinical Hospital

Hermanos Ameijeiras Surgical and Clinical Hospital, in Havana Cuba, is a center of national and international prestige. This Hospital has a recognized medical team and well-established treatments protocols in all cancer etiologies. Part of its mission is "to conduct biomedical research and clinical trials in coordination with other scientific institutions for the improvement of human health." For more information visit hospitalameijeiras.sld.cu

For More Information:

Dr. Liubov Sichel

Co-founder, Chief Scientific Officer and Chief Executive Officer, Stellar Biotics

+1 (720) 673-0772

luba@stellarbiotics.com

For Press Inquiries:

Kate Alexander

Director of Marketing Communications, Stellar Biotics

201-638-3946

kate@stellarbiotics.com